Core Viewpoint - Southbound funds have significantly increased their net purchases of Hong Kong stocks, reaching a record high of 37.213 billion HKD on March 9, 2026, despite market volatility [1][2]. Group 1: Southbound Fund Activity - On March 9, 2026, southbound funds recorded a net purchase of 37.213 billion HKD, surpassing the previous record of 35.876 billion HKD set on August 15, 2025 [1][2]. - The total net purchase amount for the year has exceeded 180 billion HKD, indicating a strong overall trend of net buying [2]. Group 2: Market Adjustments and Stock Performance - The adjustment of the Hong Kong Stock Connect stocks, effective from March 9, 2026, has attracted significant southbound capital, with 42 new stocks added to the list [3]. - The new additions to the index include major players in innovative drug development, with 12 out of 13 new stocks having a market capitalization exceeding 10 billion HKD, contributing over 240 billion HKD in market value to the index [4]. Group 3: Market Sentiment and Future Outlook - Analysts suggest that the recent surge in southbound fund inflows may be linked to the adjustments in the Hong Kong Stock Connect, with potential "front-running" behavior observed among investors [5]. - Despite a recent technical rebound in the Hong Kong market, the outlook remains cautious, with expectations of continued volatility due to external geopolitical factors and domestic economic conditions [6][8].

Financial Performance Summary - In 2025, the company achieved operating revenue of 288.27 million RMB, a decrease of 4.99% compared to the previous year [3] - The net profit attributable to the parent company was a loss of 19.09 million RMB, which represents a reduction in losses by 57.33% year-on-year [3] - Total assets at the end of the reporting period were 1.54 billion RMB, a decrease of 0.71% from the beginning of the year [3] - The equity attributable to the parent company was 1.39 billion RMB, down 1.47% from the beginning of the year [3] Operational Factors - The company continued to expand into new areas of biopharmaceutical technology, enhancing product market competitiveness and optimizing marketing strategies [4] - Despite increased sales volume due to entry into large aquaculture supply chains, revenue and gross margin slightly declined due to competitive pricing pressures in the animal health industry [4] - Delays in customer payments led to an increase in accounts receivable and higher credit impairment losses [4] - The company adjusted its operational strategy, focusing on customer needs and achieving progress in the development of multi-valent vaccines [4] Investment and Future Plans - The company invested in a stake in an innovative drug company, Yangzhou Shizhi Source Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [5] - The company plans to gain controlling interest in Shizhi Source through its wholly-owned subsidiary, Shanghai Bentiancheng Biotechnology Co., Ltd., integrating it into the consolidated financial statements [5] - Future plans include leveraging biotechnological advantages to accelerate the development and launch of innovative drugs, including treatments for HIV and allergy monoclonal antibodies [6] Credit Impairment Provision - The company plans to recognize a credit impairment provision of 12.76 million RMB for the year 2025 [11] - This provision is based on expected credit losses from accounts receivable, notes receivable, and other receivables [11] - The impact of this provision on the company's total profit for 2025 is estimated to be 12.76 million RMB, excluding tax effects [12]

Group 1 - The New Third Board continues to innovate its system to meet the financing needs of small and medium-sized enterprises, contributing to high-quality development of the real economy [1] - In 2025, the New Third Board optimized its self-managed issuance mechanism, simplifying the review process and enhancing financing efficiency, with 23 listed companies raising nearly 1.7 million yuan through self-managed issuance [1] - In 2024, 14 listed companies conducted 14 self-managed issuances, raising a total of 1.26 million yuan [1] Group 2 - Jingwei Technology, recognized as a national "little giant" enterprise, focuses on green and intelligent solutions in the electrolytic aluminum industry, raising 950,000 yuan through a private placement to enhance its R&D and market expansion capabilities [1] - Foreign enterprises are increasingly recognizing the New Third Board and Beijing Stock Exchange, with companies like CIMC ChuanKe and Keso Pharmaceuticals raising a total of 2.17 million yuan through targeted issuance for operational support and employee stock ownership plans [1] - CIMC ChuanKe, a leading manufacturer of tank and integrated systems, raised 1.1 million yuan through targeted issuance after its listing in 2024, while Keso Pharmaceuticals, focusing on innovative anti-tumor drugs, raised 650,000 yuan to support ongoing R&D [2]

Group 1 - The New Third Board continues to innovate its system to meet the financing needs of small and medium-sized enterprises (SMEs), contributing to the high-quality development of the real economy [1] - In 2025, the New Third Board optimized its self-managed issuance mechanism, simplifying the review process and enhancing financing efficiency, with 23 listed companies raising nearly 1.7 million yuan through self-managed issuance [1] - In 2024, 14 listed companies conducted 14 self-managed issuances, raising a total of 1.26 million yuan [1] Group 2 - Jingwei Technology, recognized as a national "little giant" enterprise, focuses on green and intelligent solutions in the electrolytic aluminum industry, raising 950,000 yuan through a private placement to enhance its R&D and market expansion capabilities [1] - Foreign enterprises are increasingly recognizing the New Third Board and the Beijing Stock Exchange, with companies like CIMC ChuanKe and Keso Pharmaceuticals raising a total of 2.17 million yuan through targeted issuance for operational support and employee stock ownership plans [1] - CIMC ChuanKe, a leading manufacturer of tank bodies and integrated systems, raised 11 million yuan through targeted issuance after its listing in 2024, improving its financial structure [2] - Keso Pharmaceuticals, focused on innovative anti-tumor drug development, raised 6.5 million yuan through targeted issuance in 2025, securing capital for ongoing R&D [2] - Industry insiders indicate that the New Third Board's flexible and inclusive system effectively addresses the financing gap for SMEs, with the collaboration between the Beijing Stock Exchange and the New Third Board enhancing market functions to support quality SMEs in achieving high-quality development [2]

Group 1 - The core theme of the "New Spring First Meeting" is to enhance the business environment and high-quality development, with a focus on integrating innovation and entrepreneurship [1][2] - In several cities in the Yangtze River Delta, including Nanjing, Huai'an, and Suqian, entrepreneurs were invited to sit at the main table alongside city leaders, symbolizing respect and support for business [1][4] - The "2026 Action Plan for Optimizing the Business Environment" was released, which includes establishing comprehensive service centers for enterprises and implementing a "key enterprise service specialist" system to reduce administrative burdens on businesses [2][5] Group 2 - Huai'an has held a special meeting focused on major projects and optimizing the business environment for six consecutive years on the first working day after the Spring Festival, with entrepreneurs consistently invited to the main table [4][5] - The arrangement of seating at these meetings conveys a clear message that entrepreneurs are valued partners in the city's development, enhancing their sense of honor and respect [5][6] - In Anhui's Fuyang, the meeting emphasized a consistent attitude of placing entrepreneurs in prominent positions, reinforcing the commitment to support and recognize their contributions [5]

Investment Rating - The report assigns a "Strong Buy" rating to the company for the first time [5][8]. Core Insights - The company has significant potential for value re-evaluation, particularly with its pan-KRAS inhibitors and strategic collaborations, notably with AstraZeneca [5][6]. - The first commercial product, KRAS G12C inhibitor Goleirese, has been approved and is expanding its indications, contributing to cash flow [5][33]. - The next-generation ADC platforms, tADC and iADC, are expected to overcome traditional treatment limitations and enhance the company's competitive edge in oncology [5][6][7]. Financial Summary - Projected total revenue (in million CNY) for 2024A, 2025E, 2026E, and 2027E is 156, 234, 627, and 508 respectively, with year-on-year growth rates of 145.1%, 50.5%, 167.6%, and -19.1% [5][8]. - Expected net profit attributable to shareholders (in million CNY) for the same years is -156, -15, 313, and 192, with growth rates of 56.6%, 90.7%, 2,258.6%, and -38.6% [5][8]. - The estimated price-to-earnings ratio (P/E) for 2026 is 14, and for 2027 is 23, indicating a potential for profitability [5][8]. Product Pipeline and Collaborations - The company has developed a differentiated innovation drug research system targeting difficult drug targets like KRAS, with a focus on pan-KRAS inhibitors [6][33]. - The collaboration with AstraZeneca for the pan-KRAS inhibitor JAB-23E73 is expected to accelerate the global value realization of the company's pipeline [5][6][7]. - The company is advancing its ADC platforms, with tADC utilizing KRAS inhibitors as payloads and iADC using STING agonists, aiming to address challenges in traditional therapies [5][6][7]. Market Position and Competitive Landscape - The company is positioned to leverage its innovative drug development capabilities in the oncology sector, particularly with its KRAS-targeted therapies [5][6][7]. - The competitive landscape for pan-KRAS inhibitors is evolving, with the company’s JAB-23E73 showing promising clinical data and safety profiles compared to competitors [5][6][7].

Product Development Progress - The company's recombinant anti-EpCAM/CD3 bispecific antibody M701 has received FDA approval for clinical trials to treat malignant pleural effusion, with II phase clinical trial data in China showing significant extension of patients' puncture-free survival time, which may act as a catalyst for stock price [2] - The clinical trial application for the biosimilar Y225, used for treating hemophilia A, has been approved by the National Medical Products Administration of China, further expanding the company's pipeline [2] Company Structure and Governance - Dr. Wang Tao, the employee representative supervisor, has resigned for personal career development reasons, with Dr. Shi Jian, the director of the Translational Medicine Department, taking over, indicating a need to monitor the stability of company governance following this personnel change [3] Financial Performance - The financial report for the first half of 2025 shows a year-on-year reduction in net loss, primarily due to increased revenue from R&D services resulting from a licensing collaboration with Zhengda Tianqing, with future commercial cooperation progress and cash flow improvements warranting attention [4] Industry Policy and Environment - Policies such as accelerated approval for innovative drugs continue to optimize, potentially boosting sentiment in the biotechnology sector; as a bispecific antibody development company, the value of its technology platform and pipeline may be reassessed during the industry's innovation cycle [5]

Core Viewpoint - Hite Bio plans to acquire a 23.08% stake in Beijing Shadong Biotechnology Co., Ltd. for 62.019 million yuan, increasing its ownership to 98.84%, nearly achieving full control over the company and paving the way for the commercialization of its core drug candidate CPT [2][4]. Group 1: Acquisition Details - The acquisition process began in December 2014 with a signed equity acquisition agreement involving multiple stakeholders [3]. - Hite Bio's gradual increase in stake included cash rewards and management of unexercised incentive shares to optimize Beijing Shadong's equity structure [3]. - By April 2024, Hite Bio's stake reached 75.76% through significant share acquisitions, leading to the current acquisition announcement [4]. Group 2: Strategic Importance - The primary motivation for Hite Bio's investment in Beijing Shadong is the core asset, the innovative drug CPT, which is a recombinant biologic for tumor treatment [5]. - Controlling Beijing Shadong allows Hite Bio to directly manage a valuable drug development pipeline, supporting its transition to an innovation-driven biopharmaceutical company [5]. - The acquisition will enable better resource integration and decision-making processes, preparing for CPT's clinical trials and commercialization [5]. Group 3: Future Implications - Successful approval and commercialization of CPT could significantly enhance Hite Bio's revenue and market position in the oncology sector [5]. - Full consolidation of Beijing Shadong into Hite Bio's financial statements will facilitate future planning and value maximization for the drug in global markets [5].

Group 1 - The company, Chengdu XianDao Pharmaceutical Development Co., Ltd., will hold its first extraordinary general meeting of shareholders in 2026 on March 2, 2026, at 14:00 [1][4] - The meeting will be conducted using a combination of on-site and online voting methods [1][3] - The on-site meeting will take place at the company's office located in Chengdu, Sichuan Province [1][4] Group 2 - The online voting system will be provided by the Shanghai Stock Exchange, with voting available from 9:15 to 15:00 on the day of the meeting [2][3] - Shareholders must register to attend the meeting by submitting required documents by February 27, 2026 [12][14] - The company will disclose meeting materials on the Shanghai Stock Exchange website prior to the meeting [4] Group 3 - There are no special resolutions or proposals for minority shareholders to vote separately [5] - Certain related shareholders are required to abstain from voting on specific proposals [5] - The meeting will be attended by registered shareholders, company directors, senior management, and appointed lawyers [8][9]

Core Viewpoint - Recent stock price rebound for Hotgen Biotech as innovative drug development enters a critical phase, but the company's 2025 earnings forecast indicates potential for increased losses [1] Stock Performance - On February 10, 2026, Hotgen Biotech's stock rose by 5.06%, closing at 146.44 CNY per share, with a trading volume of 134 million CNY and a total market capitalization of approximately 13.576 billion CNY [2] - Year-to-date, the stock has declined by 12.22%, but has shown a rebound trend over the last five trading days [2] - As of February 2, 2026, the company's financing balance was 154 million CNY, accounting for 1.21% of the circulating market value, which is at a relatively low level for the past year [2] Institutional Holdings Analysis - Shenwan Hongyuan Fund's product "Shenwan Hongyuan Medical Pioneer Stock A" increased its holdings in Hotgen Biotech in Q4 2025, holding 70,600 shares as of February 10, 2026, which represents 5.13% of the fund's net value, making it the third-largest holding [3] Product Development Progress - The company's globally first acute myocardial infarction therapeutic drug SGC001 has entered Phase II clinical trials, regarded as a potential catalyst in the market [4] - This pipeline is a core part of the company's "diagnostics + innovative drugs" dual-drive strategy [4] Strategic Advancement - On January 9, 2026, Hotgen Biotech signed a strategic cooperation agreement with Hebei Medical University School of Pharmacy to deepen collaboration in cutting-edge biomedical research and talent cultivation [5] - The company may benefit from industrial funds and customs facilitation policies due to its layout in the Beijing-Tianjin-Hebei region, aiding overseas market expansion [5] Performance and Operational Situation - According to earnings forecasts released on January 16 and 17, 2026, the company expects a net profit loss attributable to shareholders of 210 million to 230 million CNY for 2025, representing an increase in losses of 9.94% to 20.42% year-on-year [6] - Projected operating revenue is expected to decline to 400 million to 420 million CNY, a year-on-year decrease of 17.79% to 21.71% [6] Company Project Advancement - In December 2025, the company announced plans to invest 371 million CNY to gain controlling interest in its subsidiary Shunjing Pharmaceutical to accelerate the development of its innovative drug pipeline [7]